

# PARADIGM BIOPHARMACEUTICALS LIMITED



ASX RELEASE

7 April 2020

## PARADIGM TO HOST INVESTOR CALL TO DISCUSS US FDA REGULATORY PATHWAY, LATEST SAS REAL WORLD DATA AND CAPITAL RAISING PROCESS

**Melbourne 7 April 2020, Paradigm Biopharmaceuticals Ltd (ASX: PAR):** Paradigm is pleased to announce that it will host a conference call at 8:30am (AEST) Wednesday 8<sup>th</sup> April to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials.

Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7<sup>th</sup> April, with the company collating questions sent and will endeavour to answer the most frequently asked.

Questions are to be submitted to [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)

### Teleconference Details

You are invited to participate in a conference call held by Paradigm Biopharmaceuticals Limited CEO, Paul Rennie.

**The call is scheduled for 8:30am (AEST) Wednesday 8<sup>th</sup> April.  
(US PST 3pm / EST 6 pm on Tuesday 7<sup>th</sup>; Hong Kong 6:30am).**

### Dial-in Details

**Register for the call at the following link: <https://s1.c-conf.com/diamondpass/10005685-invite.html>**

***You will then be provided with the dial in number, the Passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.***

***To join the conference, simply dial the number in the calendar invite and enter the passcode followed by your PIN, and you will join the conference instantly.***

To learn more please visit: [www.paradigmbiopharma.com](http://www.paradigmbiopharma.com)

FOR PERSONAL USE ONLY

FOR PERSONAL USE ONLY

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

**Paradigm Biopharmaceuticals Ltd**

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email : [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)